The present invention is directed to a compound that can be used in the treatment of cancer. The compound is represented by formula (I)Further, X isIn addition, R1 is selected from H,andsubstituted or unsubstituted cyclic terpene moieties R7 and R8 are independently selected from C1 to C30 alkyl n is an integer ranging 1 to 4 and a is an integer ranging from 1 to 20. Moreover, R2 is H a Mono-phosphate, Di-phosphate, Tri-phosphate or phosphoamidite moiety or —Y—X1 or —Y-L-Y1—X1, where Y and Y1 are independently from each other a single bond or a functional connecting moiety, X1 is a colloid-active compound, a fluorescence marker, or a polynucleotide moiety having up to 50 nucleotide residues. L is a linker where Y and X1 are covalently linked together R5 and R6 represent independently from each other a C1-C28-alkyl moiety which may optionally be substituted/interrupted by one or more heteroatom(s) and/or functional group(s) a C1-C28-alkyl moiety substituted with one or more moieties selected from the group —Y—X1 or —Y-L-Y1—X1 form a ring having at least 5 members, wherein the ring may be substituted or interrupted by one or more hetero atom(s) and/or functional group(s) or R5 and R6 represent independently from each other —Y—X1 or —Y-L-Y1—X1 with the provisos that R1 and R2 are not both H and the compound comprises at least two chains each of which having 4 or more carbon atoms.
